Overview

Alzheimer’s disease and dementia are global problems, with the worldwide cost of Alzheimer’s care topping $1 trillion. An entirely new type of treatment could significantly improve quality of life for millions of patients and their families. Providing an effective treatment also represents a significant market opportunity (an estimated 40 million patients worldwide). The product also holds the potential to be effective for millions of patients suffering from mild cognitive impairment.

Alzheimer’s disease and dementia are global problems, with the worldwide cost of Alzheimer’s care topping $1 trillion. An entirely new type of treatment could significantly improve quality of life for millions of patients and their families. Providing an effective treatment also represents a significant market opportunity (an estimated 40 million patients worldwide). The product also holds the potential to be effective for millions of patients suffering from mild cognitive impairment.

Problem

Over 5 million Americans are afflicted with AD, a terminal illness that robs individuals of their memory, ability to think, and their identity. Caring for this disease is a significant burden for family members and our healthcare system. So far there is no cure and the few drugs available for treatment have limited efficacy.

Over 5 million Americans are afflicted with AD, a terminal illness that robs individuals of their memory, ability to think, and their identity. Caring for this disease is a significant burden for family members and our healthcare system. So far there is no cure and the few drugs available for treatment have limited efficacy.

Solution

Cognigenics is developing a novel, proprietary method for treating age-related symptoms of cognitive decline, including Alzheimer’s disease (AD) and dementia, as well as the accompanying problems of anxiety and depression. Our patent-pending technology targets the neurological causes of these problems using a combination of genetic, cognitive, and targeted delivery techniques.

Cognigenics is developing a novel, proprietary method for treating age-related symptoms of cognitive decline, including Alzheimer’s disease (AD) and dementia, as well as the accompanying problems of anxiety and depression. Our patent-pending technology targets the neurological causes of these problems using a combination of genetic, cognitive, and targeted delivery techniques.

Product

Cognigenics is developing a targeted RNA gene therapy for dementia designed to sharpen clarity, focus and mental acuity, while alleviating stress, depression and anxiety. Because of its novel targeted approach, it is anticipated that this treatment will provide significant benefits with little or no side effects.

Cognigenics is developing a targeted RNA gene therapy for dementia designed to sharpen clarity, focus and mental acuity, while alleviating stress, depression and anxiety. Because of its novel targeted approach, it is anticipated that this treatment will provide significant benefits with little or no side effects.

Advantage

Current symptomatic relievers for Alzheimer’s disease, including the drugs Razadyne®, Exelon® and Aricept®, have low efficacy and serious side effects. In contrast, our RNA gene therapy only affects the neurons associated with cognitive decline, thereby avoiding whole-body side effects.

Current symptomatic relievers for Alzheimer’s disease, including the drugs Razadyne®, Exelon® and Aricept®, have low efficacy and serious side effects. In contrast, our RNA gene therapy only affects the neurons associated with cognitive decline, thereby avoiding whole-body side effects.